United Therapeutics gains FDA approval for Tyvaso

07/30/2009 | American City Business Journals

The FDA cleared United Therapeutics' Tyvaso, an inhaled formulation of its injectable drug Remodulin, for pulmonary arterial hypertension. The approval comes with recommendations to make the product more patient-friendly by Oct. 31, 2010, and to test the drug for possible risks of oropharyngeal and pulmonary toxicities in patients by Dec. 15, 2013.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ